Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
254 hedge funds and large institutions have $3.79B invested in Amicus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 93 increasing their positions, 76 reducing their positions, and 18 closing their positions.
150% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 18
22% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 76
21% more call options, than puts
Call options by funds: $6.36M | Put options by funds: $5.25M
11% more funds holding
Funds holding: 228 → 254 (+26)
4.33% less ownership
Funds ownership: 113.31% → 108.98% (-4.3%)
20% less capital invested
Capital invested by funds: $4.71B → $3.79B (-$923M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$46.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$29.5M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$23.8M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$23.4M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$217M |
| 2 |
JP Morgan Chase
New York
|
-$27.6M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$22.1M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$21.1M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$20.1M |
FOLD Hedge Fund Activity: Q1 2024 in Review
254 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2024, worth a combined $3.79B — down 20% from $4.71B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new FOLD positions and 18 closed out — a net gain of 27 holders — while 93 added to existing stakes and 76 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $46.2M. The largest seller was Morgan Stanley, cutting an estimated $217M.
- 254 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2024, up from 228 in Q4 2023.
- Funds reported $3.79B of Amicus Therapeutics stock for Q1 2024, down 20% quarter-over-quarter.
- 45 funds opened new Amicus Therapeutics positions in Q1 2024 and 18 closed out, a net change of +27 holders.
- The largest Amicus Therapeutics buyer in Q1 2024 was Wellington Management Group, an estimated $46.2M added.
- The largest Amicus Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $217M sold.
Based on aggregated 13F filings for Q1 2024.